Section Arrow
Quote
SCNI.NASDAQ
- Scinai Immunotherapeutics Ltd.
Quotes are at least 15-min delayed:2025/07/20 17:11 EDT
Regular Hours
Last
 2.15
+0.0066 (+0.31%)
Day High 
2.15 
Prev. Close
2.1434 
1-M High
2.85 
Volume 
67.12K 
Bid
2.1
Ask
2.24
Day Low
2.1 
Open
2.14 
1-M Low
2.06 
Market Cap 
2.14M 
Currency USD 
P/E 1.21 
%Yield -- 
10-SMA 2.24 
20-SMA 2.29 
50-SMA 2.51 
52-W High 6.18 
52-W Low 1.9 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
--/-0.81
Enterprise Value
3.81M
Balance Sheet
Book Value Per Share
4.35
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
658.00K
Operating Revenue Per Share
0.52
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
NCNANuCana plc0.0477+0.0009+1.92%-- 
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Quotes are at least 15-min delayed：2025/07/20 17:11 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.